Skip to content
Roboearth – Lifestyle
Author:
Mabwell (Shanghai) Bioscience Co., Ltd.
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
April 15, 2026
SST001, an α-syn PET tracer from Mabwell’s incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial
April 14, 2026
←
Previous Page
1
2